<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html><head><meta http-equiv="content-type" content="text/html; charset=utf-8"/><meta name="viewport" content="width=device-width, initial-scale=0.8"/><title>Antihypertenseurs</title><link rel="stylesheet" type="text/css" href="scribble.css" title="default"/><link rel="stylesheet" type="text/css" href="manual-style.css" title="default"/><link rel="stylesheet" type="text/css" href="manual-racket.css" title="default"/><script type="text/javascript" src="scribble-common.js"></script><script type="text/javascript" src="manual-racket.js"></script><!--[if IE 6]><style type="text/css">.SIEHidden { overflow: hidden; }</style><![endif]--></head><body id="scribble-racket-lang-org"><div class="tocset"><div class="tocview"><div class="tocviewlist tocviewlisttopspace"><div class="tocviewtitle"><table cellspacing="0" cellpadding="0"><tr><td style="width: 1em;"><a href="javascript:void(0);" title="Expand/Collapse" class="tocviewtoggle" onclick="TocviewToggle(this,&quot;tocview_0&quot;);">&#9658;</a></td><td></td><td><a href="" class="tocviewselflink" data-pltdoc="x">Antihypertenseurs</a></td></tr></table></div><div class="tocviewsublistonly" style="display: none;" id="tocview_0"><table cellspacing="0" cellpadding="0"><tr><td align="right">1&nbsp;</td><td><a href="#%28part._sartans%29" class="tocviewlink" data-pltdoc="x">Sartans</a></td></tr><tr><td align="right">2&nbsp;</td><td><a href="#%28part._iec%29" class="tocviewlink" data-pltdoc="x">Inhibiteurs de l&rsquo;enzyme de conversion</a></td></tr></table></div></div></div><div class="tocsub"><table class="tocsublist" cellspacing="0"><tr><td><span class="tocsublinknumber"></span><a href="#%28part._.Antihypertenseurs%29" class="tocsubseclink" data-pltdoc="x">Antihypertenseurs</a></td></tr><tr><td><span class="tocsublinknumber">1<tt>&nbsp;</tt></span><a href="#%28part._sartans%29" class="tocsubseclink" data-pltdoc="x">Sartans</a></td></tr><tr><td><span class="tocsublinknumber">1.1<tt>&nbsp;</tt></span><a href="#%28part._sartans._pk%29" class="tocsubseclink" data-pltdoc="x">Pharmacocinetique</a></td></tr><tr><td><span class="tocsublinknumber">1.2<tt>&nbsp;</tt></span><a href="#%28part._sartans._ind%29" class="tocsubseclink" data-pltdoc="x">Indications</a></td></tr><tr><td><span class="tocsublinknumber">1.3<tt>&nbsp;</tt></span><a href="#%28part._sartans._ei%29" class="tocsubseclink" data-pltdoc="x">Effets indesirables</a></td></tr><tr><td><span class="tocsublinknumber">1.4<tt>&nbsp;</tt></span><a href="#%28part._sartans._ci%29" class="tocsubseclink" data-pltdoc="x">Contre-<wbr></wbr>indications</a></td></tr><tr><td><span class="tocsublinknumber">1.4.1<tt>&nbsp;</tt></span><a href="#%28part._.Absolue%29" class="tocsubseclink" data-pltdoc="x">Absolue</a></td></tr><tr><td><span class="tocsublinknumber">1.4.2<tt>&nbsp;</tt></span><a href="#%28part._.Relative%29" class="tocsubseclink" data-pltdoc="x">Relative</a></td></tr><tr><td><span class="tocsublinknumber">2<tt>&nbsp;</tt></span><a href="#%28part._iec%29" class="tocsubseclink" data-pltdoc="x">Inhibiteurs de l&rsquo;enzyme de conversion</a></td></tr><tr><td><span class="tocsublinknumber">2.1<tt>&nbsp;</tt></span><a href="#%28part._iec._ma%29" class="tocsubseclink" data-pltdoc="x">Mecanisme d&rsquo;action</a></td></tr><tr><td><span class="tocsublinknumber">2.2<tt>&nbsp;</tt></span><a href="#%28part._iec._ind%29" class="tocsubseclink" data-pltdoc="x">Indications</a></td></tr></table></div></div><div class="maincolumn"><div class="main"><div class="versionbox"><span class="versionNoNav">7.9</span></div><h2><a name="(part._.Antihypertenseurs)"></a>Antihypertenseurs</h2><h3>1<tt>&nbsp;</tt><a name="(part._sartans)"></a>Sartans</h3><p>Antagonistes competitifs reversibles des recepteurs a
l&rsquo;angiotensine II <span style="font-style: italic">R.AT1</span></p><p><table cellspacing="0" cellpadding="0" class="boxed" style="border-collapse: collapse;"><tr><td style="border-bottom: 1px solid black;; border-left: 1px solid black;"><p><span style="font-weight: bold">AT1</span></p></td><td valign="center" style="border-bottom: 1px solid black;; border-right: 1px solid black;"><p><span style="font-weight: bold">AT2</span></p></td></tr><tr><td style="border-bottom: 1px solid black;; border-left: 1px solid black;"><p>Vasoconstriction</p></td><td valign="center" style="border-bottom: 1px solid black;; border-right: 1px solid black;"><p>Vasodilatation</p></td></tr><tr><td style="border-bottom: 1px solid black;; border-left: 1px solid black;"><p>Vasotrophique</p></td><td valign="center" style="border-bottom: 1px solid black;; border-right: 1px solid black;"><p>anti-trophique</p></td></tr><tr><td style="border-bottom: 1px solid black;; border-left: 1px solid black;"><p>Reabsorption Na H2O</p></td><td valign="center" style="border-bottom: 1px solid black;; border-right: 1px solid black;"><p>Natriurese</p></td></tr></table></p><h4>1.1<tt>&nbsp;</tt><a name="(part._sartans._pk)"></a>Pharmacocinetique</h4><ul><li><p>Resorption digestive bonne</p></li><li><p>1er passage hepatique fort avec un metabolite actif</p></li><li><p>LPP forte</p></li><li><p>Elimination urinaire et biliaire (mixte)</p></li></ul><h4>1.2<tt>&nbsp;</tt><a name="(part._sartans._ind)"></a>Indications</h4><ul><li><p>Candesartan: <a href="https://www.icm-mhi.org/fr/soins-et-services/maladies-cardiovasculaires/insuffisance-cardiaque">Insuffisance cardiaque</a></p></li></ul><h4>1.3<tt>&nbsp;</tt><a name="(part._sartans._ei)"></a>Effets indesirables</h4><ul><li><p>Hypotension dose-dependante</p></li><li><p>Deterioration de la fonction renale</p></li><li><p>Hyperkaliemie, Hyperuricemie</p></li><li><p>Angioedeme</p></li></ul><h4>1.4<tt>&nbsp;</tt><a name="(part._sartans._ci)"></a>Contre-indications</h4><h5>1.4.1<tt>&nbsp;</tt><a name="(part._.Absolue)"></a>Absolue</h5><ul><li><p>Grossesse</p></li><li><p>Association avec les diur&#233;tiques dans les cas d&rsquo;insuffisance r&#233;nale s&#233;v&#232;re.</p></li></ul><p><span style="font-style: italic">Leur efficacit&#233; est <a href="http://www.chups.jussieu.fr/polys/pharmaco/poly/POLY.Chp.9.3.html">amoindrie par les AINS</a>.</span></p><h5>1.4.2<tt>&nbsp;</tt><a name="(part._.Relative)"></a>Relative</h5><p><a href="https://fr.wikipedia.org/wiki/St%C3%A9nose"> Stenose</a>
bilaterale des arteres renales</p><h3>2<tt>&nbsp;</tt><a name="(part._iec)"></a>Inhibiteurs de l&rsquo;enzyme de conversion</h3><h4>2.1<tt>&nbsp;</tt><a name="(part._iec._ma)"></a>Mecanisme d&rsquo;action</h4><p><a href="http://www.chups.jussieu.fr/polys/pharmaco/poly/POLY.Chp.9.3.html">Inhibiteurs de la synthese d&rsquo;angiotensine II</a>.
La cascade enzymatique est inhibee,
de la <span style="font-style: italic">synthese</span> d&rsquo;aldosterone a la <span style="font-style: italic">degradation</span> de bradykinine</p><h4>2.2<tt>&nbsp;</tt><a name="(part._iec._ind)"></a>Indications</h4><p><div class="SIntrapara"><ul><li><p>Hypertension arterielle</p></li><li><p>insuffisance cardiaque</p></li><li><p>infarctus du myocarde</p></li></ul></div><div class="SIntrapara">Leur efficacit&#233; antihypertensive est comparable &#224; celle des autres grandes
cat&#233;gories d&rsquo;antihypertenseurs.</div></p></div></div><div id="contextindicator">&nbsp;</div></body></html>